Cormedix Inc (CRMD) (Q3 2026) Earnings Call Highlights: Revenue Tops Consensus as Heron ...
Cormedix Inc (CRMD) reaffirmed full-year 2026 revenue guidance of $325 million to $345 million while announcing a transformative Heron Therapeutics asset acquisition and navigating DefenCath pricing Related Stocks: CRMD ,